B&K CORP-B(02396): The Phase II clinical trial of Pro-101-2 for treating diabetic foot ulcers has completed enrollment of all patients.
Huarong Bio-B (02396) announced that the company has completed the enrollment of all patients in the Phase II clinical trial of Pro-101-2, which is used for the treatment of diabetic foot ulcers. Pro-101-2 is one of the company's core products. This clinical trial is a randomized, double-blind, placebo-controlled study designed to further evaluate the effectiveness and safety of recombinant human platelet-derived growth factor (rhPDGF-BB) gel in treating diabetic foot ulcers, and to provide key parameters for the design of the subsequent Phase III clinical trial in a large number of enrolled subjects. The completion of patient enrollment in the Phase II clinical trial of Pro-101-2 is another significant research and development advancement for the company in the field of diabetic foot ulcer treatment.
B&K CORP-B (02396) announced that the Phase II clinical trial of Pro-101-2, developed by the company for the treatment of diabetic foot ulcers, has recently completed the enrollment of all patients. Pro-101-2 is one of the company's core products. This clinical trial is a randomized, double-blind, placebo-controlled study, aiming to further evaluate the effectiveness and safety of recombinant human platelet-derived growth factor (rhPDGF-BB) gel in treating diabetic foot ulcers, and to provide key parameters for the design of future Phase III clinical trials in a large number of enrolled subjects. The completion of patient enrollment in the Phase II clinical trial of Pro-101-2 marks another significant research and development advancement for the company in the field of diabetic foot ulcer treatment.
Related Articles
On July 13th, CARSGEN-B (02171) spent 1.8244 million Hong Kong dollars to repurchase 11.85 thousand shares.
P.B. Group (08331) receives 27.5 million shares of the company from the controlling shareholder.
Intel Corporation (INTC.US) invests an additional 5 billion euros in Ireland's Hub Group, Inc. Class A, doubling down on both data center CPU expansion and chip manufacturing outsourcing in the thriving AI arms race.
On July 13th, CARSGEN-B (02171) spent 1.8244 million Hong Kong dollars to repurchase 11.85 thousand shares.
P.B. Group (08331) receives 27.5 million shares of the company from the controlling shareholder.
Intel Corporation (INTC.US) invests an additional 5 billion euros in Ireland's Hub Group, Inc. Class A, doubling down on both data center CPU expansion and chip manufacturing outsourcing in the thriving AI arms race.
RECOMMEND
